Rubius Therapeutics went public in 2018 at a $2 billion valuation — the largest biotech stock market debut at that time. On Wednesday, the company — battered down to a market value of $15 million — said it was shutting down and liquidating all of its remaining assets.
The official end of Rubius marks one of biotech’s highest-profile flameouts. It’s also the unsurprising result of a particularly ignominious biotech financing trend: venture capitalists and their investment bankers foisting ultra-risky startups with zero clinical trial data onto the public markets.
The risk shifting has not worked out well for investors. Rubius shares have lost 99% of their value since its IPO in July 2018. Five other preclinical biotech IPOs went public around the same time as Rubius. Collectively, their stocks are down 84%.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.